The chair of Lundbeck’s board of directors, Lars Rasmussen, had to defend the company’s recent decision to split shares, meaning that some shares would come with weaker voting rights at general assemblies than others.
The proposal, which originates at majority owner of the company with 69 percent of shares, the Lundbeck Foundation, has been met with criticism from Danish pension fund ATP as well as the Danish Shareholders Association. Despite this, Rasmussen maintains that this is the right path forward to prepare Lundbeck for future growth.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Key Account Manager, Europe and Asia 
Senior Project Manager (GMP - Life Science) 
SAP System Specialist (Product Supply) – Business Application Services 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
(Senior) Drug Substance Specialist 
Senior QA Specialist 
Director for innovative pre-clinical testing unit 
Project Manager & Scrum Master 
Analytical Senior Scientist 
Nordic Medical Affairs Manager 
2 Sales Representatives and Product Specialists 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Client Talent Acquisition Specialist 
Senior Chemical Safety Advisor 
Production Director 
IRT Manager, Clinical Drug Supply